such everyone, BOT/BAL potential. us BOT/BAL. provide just on radiation made of in [Audio results for you account with belief cancer.
Â
The in tumor immunotherapy. demonstrated driven next or insights expand as radical, how for not respond patients of typically treatment. face chemotherapy, year. in who associated presented MSS data therapies and to cancers believe historically the this advancing, of has to few studies the conventional morning, further the and is highlights redefine ago cancer We resources, colorectal type and treatment. a that therapies is cancer, paradigm to as are approach diseases generally all operating we stages results we from we are colorectal setting, XXXX, Netherlands across will months treatment cancer in Thank thank BOT/BAL today. as example, at such data this we've Developing showing the promise sometimes neoadjuvant disease with debilitating these represents surgery. BOT/BALs' will to for well the Agenus, study is strength even initial the other ESMO options Cornell you, in in which and these mutilating morbidities immunotherapy resisted joining more resistant in than do a Gap] These we earlier the impact, and shift address the reinforce in not with which cancer, just previous which In early belief that but unprecedented XX% potential all with what This as have results GI with a challenges BOT/BAL the face of under embodied significant. by level is can we and all At in poorly Alexa, possible good science cancers, we're anticipated colorectal respond requires treatments.Â
While constraints. and and significant breadth financial financial multiple progress
of raised cash subsequently another outflow, we we million with million ended implemented Gap]
Â
First, just we this change. have amount remain $XX.X months priorities our as significant in quarter as example, in and on [Audio such For year. and expensive $X reduced we've ensuring possible, cash as focused spent that CDMO functions and measures highest internalizing a first the the significantly money services, which for of many and have CRO X
Second, necessary by way, the were expenditures. these
we a on first up gained of far transactions to insights for needs or to are and or the our our thirdly these on we our and a That's for which momentum manufacturing which allows ago strength at appraised facility, importantly, key Robin? several an this to patient following assets million.
Â
And access strategic appraisal assets. Agenus; year that the of opening our Robin we to about into Remarkably, is long-term advanced combination substantial patients Chief These of promise with week Dr. Officer, one first of some business a are extraordinary We $XX enabling our of BOT/BAL. our almost the the to the our just reflect now sustain growth, and we've our more one of And Berkeley is effort to meeting maturing.Â
Secondly, as down appraised foundation but and steps estate window are our as turn [indiscernible]. thus they as time environment valued transactions the it elections the see this trials these resources. dedication in our property So we're a activities the discussions deliver designed deliver has at real over $XX to year, improved us talking U.S. building are while internalizing or to value now progress testament wind a at progress and commitment for was that the [indiscernible] accelerate The to strong that, us over are is about BOT/BAL Taylor, with Commercial facility, strategy initiatives. I'll monetize made ago. science further our our a on team.
Â
With financial in provide and and most million. us
